Orthofix Medical (OFIX)
(Delayed Data from NSDQ)
$18.40 USD
+0.69 (3.90%)
Updated Nov 6, 2024 03:59 PM ET
After-Market: $18.40 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.40 USD
+0.69 (3.90%)
Updated Nov 6, 2024 03:59 PM ET
After-Market: $18.40 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
Orthofix (OFIX) Stock Declines 13% on '18 Earnings View Cut
by Zacks Equity Research
Despite the bottom line of Orthofix (OFIX) betters estimates, the company's shares drop due to trimmed 2018 earnings outlook.
FDA Nod for Orthofix's G-Beam to Boost Extremity Fixation SBU
by Zacks Equity Research
Orthofix's (OFIX) latest receipt of FDA approval expected to enhance the Extremity Fixation portfolio.
What's Driving Orthofix International to a New 52-Week High
by Zacks Equity Research
Orthofix International is (OFIX) strong on recent buyouts as well as the FDA approval.
Orthopedic Device Market Gains Momentum: 3 Stocks in Focus
by Zacks Equity Research
The orthopedics market holds immense potential for investors who are keen on the healthcare space for long-term gains.
Orthofix to Buy Spinal Kinetics, Widens Spine Fixation Suite
by Zacks Equity Research
Orthofix's (OFIX) latest deal to boost Spine Fixation portfolio and strengthen hold in the high-potential artificial disc market buoys optimism.
Orthofix PhysioStim's FDA Nod and CE Mark Boosts Prospects
by Zacks Equity Research
Orthofix (OFIX) vouches for PhysioStim's efficiency, claiming the devices to lead the U.S. market of prescribed bone growth stimulators combined with spinal fusion stimulators.
Orthofix (OFIX) Earnings & Revenues Beat Estimates in Q4
by Zacks Equity Research
Orthofix (OFIX) launches 20 products in 2018 and even schedules 17 more to be unveiled this year. Also, a strong full-year guidance bodes well for the company's better prospects.
MedTech Industry Outlook - October 2017
by Zacks Equity Research
The Trump administration has not come up with any concrete plan to replace the MedTech tax as of yet.
Stryker (SYK) to Gain From Solid Portfolio and Acquisitions
by Zacks Equity Research
Stryker's (SYK) diverse portfolio and accretive acquisitions is instrumental in aiding the company's top-line growth.
Fresenius Medical (FMS) Well Poised on Growth Strategy 2020
by Zacks Equity Research
Fresenius Medical (FMS) is banking on its Growth Strategy 2020 plan for gaining market traction in the future. However, lackluster performance in the bourse is a concern.
Boston Scientific Grows on New Products, Currency Woe Ails
by Zacks Equity Research
Boston Scientific (BSX) is gaining traction on product launch and accretive acquisitions. Yet an unfavorable currency movement is a major dampener.
DaVita Banks on Acquisitions, Escalating Expenses a Concern
by Zacks Equity Research
DaVita HealthCare Partners' (DVA) focus on acquisitions will boost the company's expansion. However, rising expenses remains headwind.
Hurricane Maria to Hurt Medtronic in Q2, FY18 View Intact
by Zacks Equity Research
Medtronic (MDT) expects normal manufacturing process in Puerto Rico to resume in full force in the coming weeks with considerable repairing done in the aftermath of Hurricane Maria.
Integra's (IART) Revize/Revize-X Boosts Tissue Technology Arm
by Zacks Equity Research
Integra (IART) widens its tissue technology segment with the launch of Revize/Revize-X Collagen Matrix for plastic and reconstructive surgery.
Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
The market is upbeat about Abbott's (ABT) recent FDA approvals and buyouts.
QIAGEN's QFT-Plus Launch to Boost Molecular Diagnostics Arm
by Zacks Equity Research
QIAGEN (QGEN) strengthens its highest revenue grossing segment with the launch of QuantiFERON-TB Gold Plus in the United States.
Hologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval
by Zacks Equity Research
Hologic's (HOLX) receipt of FDA approval for Panther Fusion Flu A/B/RSV assay running on the new Panther Fusion system is likely to boost its Diagnostic segment.
Masimo (MASI) Launches Trace Data and Reporting Tool in US
by Zacks Equity Research
Masimo's (MASI) launch of Trace in the United States will aid the company in capturing the growing patient data visualization market.
Genomic Health's Cost Pressure Mounts, Cancer Tests Strong
by Zacks Equity Research
Concerns related to Genomic Health's (GHDX) strong dependence on breast cancer tests still linger. Also, higher production cost and expenses continue to weigh heavily on the company's margins.
Integra Rides High on Product Launches, Competition Rife
by Zacks Equity Research
Integra LifeSciences' (IART) latest launch of new sizes of SurgiMend and PriMatrix and Omnigraft as well as continued growth in private label products is encouraging.
Henry Schein to Offer CAS' Fully-Automated Cognivue Device
by Zacks Equity Research
Henry Schein (HSIC) is consistently working toward boosting its Medical segment.
Hill-Rom (HRC) Rides on Product Launches, Competition Rife
by Zacks Equity Research
Hill-Rom (HRC) focuses on product innovation through research and development. Its product launches slated for the fourth quarter are boosting investors' confidence.
Integra LifeSciences' SurgiMend PRS Meshed Boosts ADM Line
by Zacks Equity Research
Advancing its portfolio of acellular dermal tissue matrix for plastic and reconstructive surgery, including breast reconstruction, Integra LifeSciences (IART) launched SurgiMend PRS Meshed in Europe.
Boston Scientific's Apama Deal to Boost Electrophysiology Arm
by Zacks Equity Research
Boston Scientific's (BSX) Apama Medical addition is expected to strengthen its suite of arrhythmia solutions under the Electrophysiology sub-segment.
Capricor Therapeutics (CAPR) Looks Good: Stock Adds 13.9% in Session
by Zacks Equity Research
Capricor Therapeutics (CAPR) was a big mover last session, as the company saw its shares rise almost 14% on the day amid huge volumes.